VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

HXN-1002 ...

Earendil Labs and Sanofi today announced that they have entered into a license agreement for two potential first-in-class ...

We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Researchers sought to evaluate preferences related to treatment features of BCMA-directed bispecific antibodies and CAR-T therapy.

Earendil Labs, an expert in AI-driven research and development of next-generation biologics therapeutics, and Sanofi have ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Earendil Labs will collaborate with Sanofi SA in a $1.8 billion license deal. Earendil, which specializes in artificial intelligence-based R&D for biologics, is getting $125 million up front and $50 ...

Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 ...

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...